Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
Stocks in this Quantisnow insightHealth Care
Historical context for CLDI
Across the 27 sessions after earlier CLDI headlines, the stock closed higher 11 times and lower 16 times, with a median move of 4.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CLDI | SPY |
|---|---|---|---|
| Oct 19, 2026 | Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 | -6.4% | +0.4% |
| Sep 28, 2026 | Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency | -5.3% | -0.7% |
| Sep 17, 2026 | Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering | +8.5% | +1.1% |
| Sep 8, 2026 | Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | -2.5% | -0.5% |
| Aug 14, 2026 | Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | +3.2% | -0.2% |
| Jul 27, 2026 | Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference | +9.5% | +0.0% |
Quantisnow market dataAMEX
CLDI
Calidi Biotherapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for CLDI
Full CLDI profile on Quantisnow Follow CLDI and get a push notification the moment its next story breaks.